- Home
- APLM vs IHT Comparison
APLM vs IHT Comparison
Compare APLM & IHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- IHT
- Stock Information
- Founded
- APLM 2016
- IHT 1971
- Country
- APLM United States
- IHT United States
- Employees
- APLM N/A
- IHT N/A
- Industry
- APLM Blank Checks
- IHT Investment Bankers/Brokers/Service
- Sector
- APLM Finance
- IHT Finance
- Exchange
- APLM Nasdaq
- IHT Nasdaq
- Market Cap
- APLM 15.6M
- IHT 18.0M
- IPO Year
- APLM N/A
- IHT N/A
- Fundamental
- Price
- APLM $9.75
- IHT $2.28
- Analyst Decision
- APLM Strong Buy
- IHT
- Analyst Count
- APLM 2
- IHT 0
- Target Price
- APLM $425.00
- IHT N/A
- AVG Volume (30 Days)
- APLM 107.4K
- IHT 2.5K
- Earning Date
- APLM 02-15-2025
- IHT 12-31-2024
- Dividend Yield
- APLM N/A
- IHT 0.88%
- EPS Growth
- APLM N/A
- IHT N/A
- EPS
- APLM N/A
- IHT N/A
- Revenue
- APLM $2,101,000.00
- IHT $7,692,305.00
- Revenue This Year
- APLM N/A
- IHT N/A
- Revenue Next Year
- APLM N/A
- IHT N/A
- P/E Ratio
- APLM N/A
- IHT N/A
- Revenue Growth
- APLM 70.54
- IHT 4.55
- 52 Week Low
- APLM $6.50
- IHT $1.22
- 52 Week High
- APLM $105.00
- IHT $2.36
- Technical
- Relative Strength Index (RSI)
- APLM 50.39
- IHT 59.17
- Support Level
- APLM $7.23
- IHT $2.06
- Resistance Level
- APLM $8.88
- IHT $2.24
- Average True Range (ATR)
- APLM 1.37
- IHT 0.13
- MACD
- APLM 0.21
- IHT -0.00
- Stochastic Oscillator
- APLM 57.91
- IHT 100.00
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.